Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancerCarmen Criscitiello, Giuseppe Curigliano, Andrea Vingiani et al.|Breast Cancer Research and Treatment|2020Cited by 102
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancerDavide Massa, Maria Vittoria Dieci, Silvia Brich et al.|JNCI Journal of the National Cancer Institute|2024Cited by 32
1MO Tumor immune microenvironment in ER-negative vs ER-low, HER2-neg breast cancerDavide Massa, Maria Vittoria Dieci, Claudio Vernieri et al.|ESMO Open|2023Cited by 4
Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC TrialFederica Miglietta, Maria Vittoria Dieci, Manon de Graaf et al.|Clinical Cancer Research|2025Cited by 1
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapySara Pizzamiglio, Serena Di Cosimo, Adriana Blanda et al.|npj Breast Cancer|2025Cited by 1